核心医疗科创板IPO申请获受理 高瓴再被认定为“资深专业机构投资者”

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, marking a significant step in its growth and development in the high-end medical device sector [1] Company Summary - Core Medical was established in August 2016 and focuses on the research and production of mechanical circulatory support devices, commonly known as "artificial hearts," achieving comprehensive layout in the field of implanted and interventional artificial hearts [1] - The company has attracted investments from several reputable institutional investors, including Zhuhai Hillhouse and Zhengxin Valley Investment, indicating strong market confidence in its business model and growth potential [1] Industry Context - The recent "1+6" policy introduced by the Sci-Tech Innovation Board aims to support high-quality, unprofitable technology companies in going public, which includes the establishment of a growth tier and the introduction of professional institutional investors [1] - The relevant supporting rules were officially implemented in July, enhancing the regulatory framework for companies like Core Medical seeking to leverage the capital markets for growth [1]